Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy : Payer Perspective in Turkey

© 2021. The Author(s)..

INTRODUCTION: This study aims to evaluate the cost-effectiveness of remdesivir compared to other existing therapies (SoC) in Turkey to treat COVID-19 patients hospitalized with < 94% saturation and low-flow oxygen therapy (LFOT) requirement.

METHODS: We compared remdesivir as the treatment for COVID-19 with the treatments in the Turkish treatment guidelines. Analyses were performed using data from 78 hospitalized COVID-19 patients with SpO2 < 94% who received LFOT in a tertiary healthcare facility. COVID-19 episode costs were calculated for 78 patients considering the cost of modeled remdesivir treatment in the same group from the payer's perspective. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) was calculated for remdesivir versus the SoC for the population identified. For Turkey, a reimbursement threshold value between USD 8599 (1 × per capita gross domestic product-GDP) and USD 25.797 (3 × GDP) per QALY was used.

RESULTS: In the remdesivir arm, the length of hospital stay (LOS) was 3 days shorter than the SOC. The low ventilator requirement in the remdesivir arm was one factor that decreased the QALY disutility value. In patients who were transferred to intensive care unit (ICU) from the ward, the mean LOS was 17.3 days (SD 13.6), and the mean cost of stay was USD 155.3/day (SD 168.0), while in patients who were admitted to ICU at baseline, the mean LOS was 13.1 days (SD 13.7), and the mean cost of stay was USD 207.9/day (SD 133.6). The mean cost of episode per patient was USD 3461.1 (SD 2259.8) in the remdesivir arm and USD 3538.9 (SD 3296.0) in the SOC arm. Incremental QALYs were estimated at 0.174. Remdesivir treatment was determined to be cost saving vs. SoC.

CONCLUSIONS: Remdesivir, which results in shorter LOS and lower rates of intubation requirements in ICU patients than existing therapies, is associated with higher QALYs and lower costs, dominating SoC in patients with SpO2 < 94% who require oxygen support.

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

Advances in therapy - Vol. 38, No. 9 (2021), p. 4935-4948

Language:

English

Contributors:

Oksuz, Ergun
Malhan, Simten
Gonen, Mustafa Sait
Kutlubay, Zekayi
Keskindemirci, Yilmaz
Jarrett, James
Sahin, Toros
Ozcagli, Gokcem
Bilgic, Ahmet
Bibilik, Merve Ozlem
Tabak, Fehmi

Links:

Volltext

Keywords:

*COVID-19
3QKI37EEHE
415SHH325A
Adenosine Monophosphate
Alanine
COVID-19
Cost-Benefit Analysis
Cost-effectiveness
Humans
Journal Article
Length of stay
OF5P57N2ZX
Oxygen
Oxygen saturation
QALYs
Remdesivir
Research Support, Non-U.S. Gov't
S88TT14065
SARS-CoV-2
Turkey

Notes:

Date Completed 03.09.2021

Date Revised 03.09.2021

published: Print-Electronic

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1007/s12325-021-01874-9

PMID:

34379304

PPN (Catalogue-ID):

NLM330409999